Evofem Biosciences, INC

Evofem Biosciences has released a corporate slide presentation providing business updates to the investment community.

Evofem Biosciences has entered into a subordinated note agreement with HUB Cyber Security, Ltd. for $706,304, bearing 12% annual interest.

Evofem Biosciences reported Q1 2026 net sales of $0.9 million, a slight increase from the prior year, while focusing on international commercialization and cost reduction initiatives.

Evofem Biosciences has entered into a fourth amendment to its 2020 Securities Purchase Agreement, extending the maturity date of its convertible promissory notes by six months.

Evofem Biosciences and Windtree Therapeutics mutually agreed to terminate their License and Supply Agreement for PHEXXI manufacturing due to Windtree's failure to establish production capabilities.

Evofem Biosciences, Inc. announced it has posted an updated corporate slide presentation to its investor website, providing a summary of its business.

Evofem Biosciences reports a $5.5 million quarterly loss and warns of substantial doubt regarding its ability to continue as a going concern despite expanding its product portfolio.

Evofem Biosciences reported Q3 2025 results, terminating its merger with Aditxt, facing substantial doubt about its ability to continue as a going concern, and navigating multiple debt defaults.

Evofem Biosciences reports continued operating losses and significant liquidity concerns, relying on a pending merger with Aditxt and new product commercialization to sustain operations.

Evofem Biosciences reports a net income of $956,000 for Q1 2025, but faces going concern uncertainties due to a working capital deficit and accumulated losses.

Evofem Biosciences has entered into new employment agreements with its CEO and CFO, outlining their roles, responsibilities, and compensation.

Evofem Biosciences' Q2 2024 results show a complex financial picture with increased product sales offset by significant operating expenses and strategic moves including a merger and acquisition.

Evofem Biosciences files an amendment to its annual report on Form 10-K to correct an error in the independent auditor's consent regarding the audit opinion and fiscal year-end dates.

Evofem Biosciences reports its annual results, highlighting ongoing financial challenges and the potential impact of the Aditxt merger, while navigating market competition and regulatory landscapes.

Evofem Biosciences reports its 2023 financial results, highlighting a revenue increase despite reduced unit sales, while also navigating a merger agreement with Aditxt.

Evofem Biosciences, a women's health company, is seeking stockholder approval for a reverse stock split to meet Nasdaq listing standards and enable a critical capital raise, following a year of mixed financial performance and a terminated merger.

Evofem Biosciences announced a new date for its Special Meeting of Stockholders and clarified the availability of dissenters' rights for shareholders.

Evofem Biosciences anticipates stockholder approval of its merger with Aditxt at a special meeting on September 26, 2025.

Evofem Biosciences announced a special meeting of stockholders to vote on a merger agreement with Aditxt, Inc., with the transaction expected to close in the second half of 2025.

Evofem Biosciences, Inc. has increased its authorized Series E-1 Preferred Stock to 10,000 shares, primarily to facilitate dividend payments in kind, following approval by preferred stockholders and the Board.

HUB Cyber Security Ltd. has acquired significant convertible notes and purchase rights in Evofem Biosciences, Inc., signaling a strategic investment and potential collaboration.